Aptima®+ThinPrep® Cervical Health

Leading the charge in cervical disease prevention with the ThinPrep® system and Aptima® HPV assays

Hologic has remained an unwavering advocate for women’s health for more than two decades. Our goals as a company are intrinsically tied to changes in best-practices for women’s health, applying the latest findings in diagnostic medicine to the development of new products and technologies in response to the emergence of new discoveries in medicine.

Cervical disease screening is an essential component of our efforts in women’s health. Hologic is the leader in Pap and human papillomavirus (HPV) testing. The ThinPrep® Pap test helps healthcare providers detect the presence of abnormal cervical cells, and the Aptima HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease.1-3

The path to defeating cervical cancer

Today, screening with Pap+HPV Together™ (co-testing) provides the best possible protection against cervical cancer for women ages 30-65.4-6 Now, what was once a top cancer among women is up to 93% preventable.7

The introduction of the Pap smear and later, the ThinPrep Pap test, have contributed to a decline in cervical cancer rates of more than 60% since the 1950s.1,8 Since then, HPV has been identified as a cause of cervical cancer, and HPV testing and vaccinations have been developed.9

These medical triumphs have fortified the medical community’s ability to detect and prevent cervical disease and cancer. Today, the combination of data-supported guidelines for cervical cancer screening and the availability of HPV vaccination are key in the fight for cervical health.

Cervical cancer screening guidelines help mitigate risk

The American Congress of Obstetricians and Gynecologists (ACOG) delivers guidelines for cervical cancer screening. For women ages 30-65, this means Pap+HPV Together.6

ACOG recommends:

Pap-alone screening for women ages 21-29.6

Co-testing for women ages 30-65.6

At Hologic, we believe in delivering precision testing that helps women live healthier without enduring a disease that is largely preventable with accurate screening.7 Our tests are designed to help providers Be Sure when it comes to screening. The ThinPrep Pap test is the most widely used Pap test in the United States.10 The Aptima HPV assays identify high-risk HPV infections by targeting E6/E7 mRNA.2,3

The ThinPrep Pap test: First in liquid-based cytology

Hologic released the first FDA-approved, liquid-based cytology option in cervical disease screening in 1996: the ThinPrep Pap test.1 Today, more than 20 years after the release of the ThinPrep Pap test, it remains the preferred choice in Pap testing in the United States.10 ThinPrep Pap tests account for more than 80% of Pap tests performed in the United States, with 650 million tests performed globally so far.10

The College of American Pathologists reported increased HSIL (high-grade squamous intraepithelial lesions) and LSIL (low-grade squamous intraepithelial lesions) in labs using liquid-based cytology versus labs that used conventional Pap testing.12 It also showed increased sensitivity for cervical adenocarcinoma over conventional Pap testing.13

The ThinPrep Pap test is the only liquid-based Pap test FDA approved for use with all current FDA-approved HPV tests.* It is also FDA cleared for Chlamydia, gonorrhea and trichomoniasis testing from the same vial.1,14

HPV testing for precision detection and risk stratification

The Aptima® HPVassay and Aptima®HPV 16 18/45 genotype assay target HPV types that pose the largest threat to women.2,3 While other HPV assays target DNA, the Aptima HPV assays target mRNA, which studies show reflects the presence and activity of high-risk HPV infection.2,3 The Aptima HPV assay detects E6/E7 mRNA, which is indicative of those HPV infections more likely to cause cervical disease.2 The Aptima HPV 16 18/45 genotype assay identifies HPV types 16, 18 and 45, which are associated with up to 80% of all invasive cervical cancers worldwide.3,15-16

The ThinPrep system helps optimize lab workflow

The ThinPrep Pap test is just one of several offerings in the ThinPrep system. The ThinPrep processors, imagers and review scopes help improve workflow in laboratories and assist with cytotechnologists’ ability to identify abnormalities. These instruments help complete the ThinPrep system and maximize laboratory efficiency and accuracy in disease detection.

In addition to the ThinPrep Pap test, Hologic remains committed to providing laboratories with innovative and effective cytology solutions for non-gynecological testing needs.

Processors

ThinPrep® 2000 Processor: Scalable solution for compact work environments; the versatile workhorse that started the ThinPrep revolution.

From Pap and HPV testing to our full range of diagnostic products and cross-divisional innovations like the Genius™ 3D Mammography™ exam for breast health, Hologic delivers for women. Our promise to offer innovative products to meet the needs of women globally persists throughout all that we do, including in cervical disease screening. Working together, we can achieve the goal of defeating cervical disease.

A multifaceted approach for women’s holistic health

To learn more about the Aptima + ThinPrep Cervical Health portfolio, visit HealthDxS.com.

Information provided on this tab is intended for audiences outside the United States. Consult "USA" tab for products and claims available in the United States.

Leading the charge in cervical disease prevention with the ThinPrep system and Aptima HPV assays

Hologic has remained an unwavering advocate for women’s health for more than two decades. Our goals as a company are intrinsically tied to changes in best-practices for women’s health, applying the latest findings in diagnostic medicine to the development of new products and technologies in response to the emergence of new discoveries in medicine.

Cervical disease screening is an essential component of our efforts in women’s health. Hologic is the leader in Pap and human papillomavirus (HPV) testing. The ThinPrep Pap test helps healthcare providers detect the presence of abnormal cervical cells, and the Aptima HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease.1-3

The path to defeating cervical cancer

Today, screening with Pap+HPV Together (co-testing) provides the best possible protection against cervical cancer for women ages 30-65.4-6 Now, what was once a top cancer among women is up to 93% preventable.7

The introduction of the Pap smear and, later the ThinPrep Pap test, have contributed to a decline in cervical cancer rates of more than 60% since the 1950s.1,8 Since then, HPV has been identified as a cause of cervical cancer, and HPV testing and vaccinations have been developed.9

These medical triumphs have fortified the medical community’s ability to detect and prevent cervical disease and cancer. Today, the combination of data-supported guidelines for cervical cancer screening and the availability of HPV vaccination are key in the fight for women’s health.

The ThinPrep Pap test: First in liquid-based cytology

Hologic released the first liquid-based cytology option in cervical disease screening in 1996: the ThinPrep Pap test.1 Today, more than 20 years after the release of the ThinPrep Pap test, it remains the preferred choice in Pap testing in the United States.10 ThinPrep Pap tests account for more than 80% of Pap tests performed in the United States, with 650 million tests performed globally so far.10

HPV testing for precision detection and risk stratification

The Aptima HPV assay and Aptima HPV 16 18/45 genotype assay target HPV types that pose the largest threat to women.2,3 While other HPV assays target DNA, the Aptima HPV assays target mRNA, which studies show reflects the presence and activity of high-risk HPV infection.2,3 The Aptima HPV assay detects E6/E7 mRNA, which is indicative of those HPV infections more likely to cause cervical disease.2 The Aptima HPV 16 18/45 genotype assay identifies HPV types 16, 18 and 45, which are associated with up to 80% of all invasive cervical cancers worldwide.3,14-15

The ThinPrep system helps optimize lab workflow

The ThinPrep Pap test is just one of several offerings in the ThinPrep system. The ThinPrep processors, imagers and review scopes help improve workflow in laboratories and assist with cytotechnologists’ ability to identify abnormalities. These instruments help complete the ThinPrep system and maximize laboratory efficiency and accuracy in disease detection.

In addition to the ThinPrep Pap test, Hologic remains committed to providing laboratories with innovative and effective cytology solutions for non-gynecological testing needs.

Processors

ThinPrep 2000 Processor: Scalable solution for compact work environments; the versatile workhorse that started the ThinPrep revolution

Imagers and Review Scopes

ThinPrep Image Processor: Identifies 22 areas of interest within the ThinPrep Pap test slides with the largest, darkest nuclei for cytotechnologists to examine

ThinPrep Integrated Imager: ThinPrep imaging and slide review technology in a single device.

ThinPrep Rview Scope: Presents the 22 fields of view to the cytotechnologist for his or her review

ThinPrep Review Scope Manual+: Combines the power of the review scope with the flexibility of a manual microscope

From Pap and HPV testing to our full range of diagnostic products and cross-divisional innovations like the Genius™ 3D Mammography exam for breast health, Hologic delivers for women. Our promise to offer innovative products to meet the needs of women globally persists throughout all that we do, including in cervical disease screening. Working together, we can achieve the goal of defeating cervical disease.

A multifaceted approach for women’s holistic health

To learn more about the Aptima + ThinPrep Cervical Health portfolio, visit HealthDxS.com.